Topics

Incyte pays big for rights to MorphoSys's tafasitamab

14:40 EST 15 Jan 2020 | Elsevier Business Intelligence

In a deal potentially worth up to $2bn, Incyte Corp. licensed exclusive global rights to develop and sell MorphoSys AG’s an...

Original Article: Incyte pays big for rights to MorphoSys's tafasitamab

NEXT ARTICLE

More From BioPortfolio on "Incyte pays big for rights to MorphoSys's tafasitamab"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...